Optimization and comparison of knockdown efficacy between polymerase II expressed shRNA and artificial miRNA targeting luciferase and Apolipoprotein B100 by Piotr Maczuga et al.
Maczuga et al. BMC Biotechnology 2012, 12:42
http://www.biomedcentral.com/1472-6750/12/42RESEARCH ARTICLE Open AccessOptimization and comparison of knockdown
efficacy between polymerase II expressed shRNA
and artificial miRNA targeting luciferase and
Apolipoprotein B100
Piotr Maczuga1,2, Annemart Koornneef1, Florie Borel1,3, Harald Petry1, Sander van Deventer2, Tita Ritsema1
and Pavlina Konstantinova1*Abstract
Background: Controlling and limiting the expression of short hairpin RNA (shRNA) by using constitutive or
tissue-specific polymerase II (pol II) expression can be a promising strategy to avoid RNAi toxicity. However, to
date detailed studies on requirements for effective pol II shRNA expression and processing are not available. We
investigated the optimal structural configuration of shRNA molecules, namely: hairpin location, stem length and
termination signal required for effective pol II expression and compared it with an alternative strategy of avoiding
toxicity by using artificial microRNA (miRNA) scaffolds.
Results: Highly effective shRNAs targeting luciferase (shLuc) or Apolipoprotein B100 (shApoB1 and shApoB2) were
placed under the control of the pol II CMV promoter and expressed at +5 or +6 nucleotides (nt) with reference to
the transcription start site (TSS). Different transcription termination signals (TTS), namely minimal polyadenylation
(pA), poly T (T5) and U1 were also used. All pol II- expressed shRNA variants induced mild inhibition of Luciferase
reporters carrying specific targets and none of them showed comparable efficacy to their polymerase III-expressed
H1-shRNA controls, regardless of hairpin position and termination signal used. Extending hairpin stem length from
20 basepairs (bp) to 21, 25 or 29 bp yielded only slight improvement in the overall efficacy. When shLuc, shApoB1
and shApoB2 were placed in an artificial miRNA scaffold, two out of three were as potent as the H1-shRNA controls.
Quantification of small interfering RNA (siRNA) molecules showed that the artificial miRNA constructs expressed less
molecules than H1-shRNAs and that CMV-shRNA expressed the lowest amount of siRNA molecules suggesting that
RNAi processing in this case is least effective. Furthermore, CMV-miApoB1 and CMV-miApoB2 were as effective as the
corresponding H1-shApoB1 and H1-shApoB2 in inhibiting endogenous ApoB mRNA.
Conclusion: Our results demonstrate that artificial miRNA have a better efficacy profile than shRNA expressed either
from H1 or CMV promoter and will be used in the future for RNAi therapeutic development.Background
RNA interference (RNAi) is an evolutionary conserved
mechanism for regulating gene expression. It plays an
important role in defense against viruses but also in
development and in normal functioning of the cell
[1,2]. The natural RNAi mechanism functions by en-
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transcripts (pri-miRNAs). Pri-miRNAs are cleaved by
the nuclear Drosha-DGCR8 complex to produce
miRNA precursors (pre-miRNAs) of 70 nucleotides
(nt), which are then transported by Exportin 5 to the
cytoplasm and processed by the RNAse III endonucle-
ase family enzyme Dicer to produce a mature miRNA
duplex of ~21,22 basepairs (bp). The guide strand of
the miRNA enters a multiprotein RNA-induced silen-
cing complex (RISC) where it is used for sequence-
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get mRNA results in transcript degradation or transla-
tional repression [3].
By introducing molecules that constitute substrates for
the endogenous RNAi pathway disease-related mRNA
and thus protein translation can be inhibited. RNAi in
cells can be induced in different ways. Generally this is
achieved by delivery of 20–25 bp-long small interfering
RNAs (siRNAs) [4] which serve as substrates for the
RISC complex. Alternatively, siRNAs can be generated
by expressing short hairpin RNA (shRNA) [5] or artifi-
cial microRNA (miRNA) structures [6]. Both enter the
endogenous RNAi pathway and are processed into ma-
ture siRNAs. The crucial difference between shRNAs
and artificial miRNAs is in their secondary structure and
processing in the RNAi pathway. shRNAs are normally
expressed from polymerase III (pol III) promoters and
directly generate a mature product which is exported
and processed by Dicer, while miRNAs require an add-
itional step of excision from the longer pre-miRNA se-
quence by the Drosha-DGCR8 complex. Moreover,
miRNAs are expressed from polymerase II (pol II) pro-
moters that allow for the use of tissue-specific or regu-
lated expression systems.
To date, shRNA expression from pol III promoters is
the most common way to induce RNAi in cells, which
provides potent and stable target inhibition. Several pol
III promoters are being used for expression of shRNAs,
such as H1 or U6, and transcription initiation and ter-
mination sites together with the structural requirements
for effective expression of the hairpins are well
described [7,8]. However, there are serious disadvan-
tages of pol III expression systems which question their
possible application as therapeutic agents. There are
cases reporting severe toxicity after administration of
high doses of vectors encoding shRNA [9,10]. Toxicity
was shown to be associated with oversaturation of the
cellular RNAi machinery and changes in endogenous
miRNA expression.
This toxicity problem may be circumvented by using
weaker pol II promoter to express shRNAs or by embed-
ding siRNA into artificial miRNA scaffolds. The CMV
promoter has been the first pol II promoter shown to
express active shRNA and initial requirements for this
approach have been established: the shRNA has to be
juxtaposed to the transcription start site (TSS) (within 6
nt) and followed by the minimal polyadenylation signal
(pA) [11]. When these two conditions were not met, the
shRNA was found to be inactive. Additionally, to limit
toxicity tissue-specific pol II promoters which restrict
expression to the target tissue can be applied. This ap-
proach has been used to safely express shRNAs targeting
JNK1, JNK2, and PI3 under the control of the prostate-
specific antigen pol II promoter in androgen-responsivecancer cells [12]. Furthermore, in vivo toxicity related to
high shRNA expression levels from a pol III promoter
was abolished when the shRNA was expressed from the
liver-specific pol II hAAT promoter and U1 termination
signal was used [13]. Incorporation of a siRNA sequence
in an artificial miRNA scaffold has been shown to abol-
ish shRNA-induced neuronal cell death and to avoid dis-
ruption of the endogenous RNAi pathway [6,14].
In the current study we focused on the structural
requirements to determine the optimal configuration for
pol II shRNA expression and compared it to the pol II
expression of artificial miRNA. To date, no detailed
studies on the hairpin positions, transcription termin-
ation signal (TTS), and shRNA stem length require-
ments for efficient pol II shRNA expression have been
performed. Varying positions of the hairpin relative to
the TSS +5 or +6, stem length of 20, 21, 25, 29 bp and
different TTS (pA, U1 and T5) have been tested for a
shRNA targeting luciferase (shLuc) and expressed from
the pol II CMV promoter. shLuc at +6 location relative
to TSS, with stem length of 20 nt with either pA or U1
termination signal was found to yield optimal results.
However, the average luciferase inhibition of 40% was
still lower than the control pol III H1-shRNA, which
inhibited luciferase up to 90%. Additionally, two shRNAs
targeting ApoB (shApoB1 and shApoB2) were found in-
active when expressed from CMV using the same con-
figuration. In contrast, when the three shRNAs were
incorporated in an artificial miRNA scaffold, two were
equally active to their respective H1-shRNA controls
while expressing much less siRNA molecules. This indi-
cates that using artificial miRNA scaffolds has a greater
therapeutic potential than direct expression of shRNAs
from pol II promoters.
Results
Design and knockdown efficacy of CMV-shLuc with
different transcription start and transcription termination
signals
Previously, we have identified a highly effective siRNA
potent in knocking down luciferase when expressed as
shRNA from the pol III H1 promoter (shLuc) [15]. To
minimize the risk of inducing toxic effects due to siRNA
over expression we wanted to express the same shLuc
sequence under the control of the pol II CMV promoter.
In contrast to pol III, most pol II transcripts undergo
posttranscriptional modification at the 5' and 3' ends,
which enhances their stability and protects them from
degradation [16]. However, both 5’ and 3’ overhangs of
the shRNA are important for correct recognition and
processing by Dicer [17] therefore these sequences
needed to be optimized. A panel of shLuc constructs
with perfect complementary 20-bp shRNA stem and 9-
nt loop was expressed from the pol II CMV promoter
a b
Figure 1 Structure and knockdown efficacy of short hairpins targeting luciferase (shLuc) with different TSS and different TTS. (a)
Schematic representation of shLuc constructs expressed from H1 and CMV promoters. Different TTS (pA, T5 and U1) are presented. Hairpin
location (+5 or +6) is shown with reference to the TSS (set as +1). The shLuc consists of 20 nt perfectly complementary hairpin structure and a
loop of 9 nt. (b) Luciferase knockdown by CMV-shLuc with different TSS and different TTS. Renilla and Firefly luciferase were measured two days
post-transfection with 2,5 ng Firefly luciferase reporter, 0,5 ng Renilla luciferase and 100 ng shLuc expressing plasmids. Firefly luciferase expression
was normalized to Renilla luciferase expression. H1-shLuc was used as a positive control, H1-shGFP and CMV-shGFP served as negative controls
and were set at 100%. Data are represented as mean values ± SD from three independent experiments analyzed with the factor correction
method [19]. **p< 0.01 versus negative control One-way ANOVA test with Bonferroni post test.
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promoter, followed by a minimal pA signal. The begin-
ning of the passenger strand of the shLuc sequence was
placed at positions +5 or +6 relative to the TSS generat-
ing CMV+5shLuc-pA and CMV+6shLuc-pA, respect-
ively (Figure 1a). It has been reported that T5 TTS can
be used instead of pA signal in a CMV-shRNA expres-
sion cassette [18]. Therefore, this termination signal was
used in the +5shLuc and +6shLuc constructs instead of
pA, resulting in CMV+5shLuc-T5 and CMV+6shLuc-
T5. Finally, the U1 termination signal was cloned behind
+6shLuc, resulting in CMV+6shLuc-U1. To compare
their inhibitory effect, HEK293T cells were co-
transfected with the different variants of CMV-shLuctogether with the Firefly luciferase reporter. shRNA tar-
geting GFP (shGFP) was included as a negative control
and Renilla luciferase expression was measured to cor-
rect for experimental conditions. The ratio Firefly/
Renilla in the negative control was set as 100% and rela-
tive inhibition of the luciferase reporter was calculated.
All CMV-shLuc constructs appeared less effective in
inhibiting luciferase compared to the pol III H1-shLuc
control (Figure 1b). The maximum inhibition of lucifer-
ase achieved was 22% and 36% for CMV+5shLuc-pA
and CMV+6shLuc-pA constructs, respectively. CMV+6
shLuc-U1 inhibited luciferase expression with only 18%.
CMV+5shLuc-T5 and CMV+6shLuc-T5 constructs
were not effective at all.
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different hairpin stem length
The length of the stem in the shRNA has been found
to be important for Dicer processing resulting in en-
hancement of the silencing potential of a given hairpin
[20]. Dicer recognizes double-stranded RNA and cleaves
21–22 nt to produce mature siRNA. To check whether
extending stem length of shLuc would improve its effi-
cacy as a result of better Dicer processing, constructs
with 20, 21, 25 and 29 bp stem were designed by
extending the 5’ end of the guide strand, resulting in
shLuc20, shLuc21, shLuc25 and shLuc29 variants
(Figure 2a). Based on our previous findings shLuc was
placed at +6 site and followed by pA or U1 termination
signal. Luciferase knockdown was measured to deter-
mine the efficacy of the extended stem length con-
structs (Figure 2b,c). Improved efficacy was observed
when extending hairpin stem to 21 bp for both pAFigure 2 Structure and knockdown efficacy of CMV-shLuc with differe
termination signals (U1). (a) Predicted stem-loop structure of CMV-shLuc
highlighted in grey (b) Luciferase knockdown by CMV-shLuc20, CMV-shLuc
signal. (c) Luciferase knockdown by CMV-shLuc20, CMV-shLuc21, CMV-shLu
Firefly luciferase were measured two days post-transfection with 2,5 ng Fire
hairpin expressing plasmid. Firefly luciferase expression was normalized to
H1-shScr and CMV-shScr served as negative controls and were set at 100%
experiments analyzed with the factor correction method [19]. *p< 0.05, **p
post test).(Figure 2b) and U1 TTS (Figure 2c). This improvement
was statistically significant for pA TTS (p< 0,05) while
change for U1 TTS was not significant (p>0,05). Fur-
ther lengthening of the shLuc hairpin stem to 25 and
29 bp did not change the inhibitory effect of these con-
structs (Figure 2b,c).
Design and knockdown efficacy of CMV-shRNA and
artificial miRNA targeting luciferase or Apolipoprotein
B100 (ApoB)
Previously, H1-shApoB1 and H1-shApoB2 have been
used to inhibit in vitro and in vivo the expression of
ApoB that is the structural protein of low density lipo-
protein cholesterol (LDL-C) [21] (and data not shown).
To evaluate whether the structural requirements for ex-
pression of shRNA from the CMV promoter, +6 TSS and
pA TTS apply not only to luciferase-targeting constructs,
two CMV-shRNAs targeting ApoB were designed andnt stem length and polyadenylation (pA) or U1 transcription
with different stem lengths (20, 21, 25 and 29 bp). Guide strand is
21, CMV-shLuc25, CMV-shLuc29 with pA transcription termination
c25, CMV-shLuc29 with U1 transcription termination signal. Renilla and
fly luciferase reporter, 0,5 ng Renilla luciferase and 100 ng short
Renilla luciferase expression. H1-shLuc was used as a positive control.
. Data are represented as mean values + SD from three independent
< 0.01 versus negative control (One-way ANOVA test with Bonferroni
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As an alternative strategy for direct pol II expression of
shRNA, artificial miRNA scaffolds incorporating siRNA
targeting luciferase or ApoB were designed by substitut-
ing the mature miRNA sequence with luciferase and
ApoB target sequences, resulting in CMV-miLuc, CMV-
miApoB1 and CMV-miApoB2 (Figure 3a,b,c). The pri-
miRNA structure contains additional flanking sequences
at the 5' and 3' ends of the hairpin, which enables correct
recognition and processing by the RNAi pathway
enzymes Drosha and Dicer. The 5' and 3' flanking
sequences of pri-mir155 were used, therefore design and
optimization of the sequences up- or downstream of the
miRNA hairpin are not required for effective knockdown.
Knockdown efficacy of CMV-shRNAs and CMV-
miRNAs was determined on their specific luciferase
reporters, containing ApoB target sequences in case of
shApoB and miApoB constructs. H1-shLuc, H1-shApoB1
and H1-shApoB2 were used as positive controls and
H1-shScr, CMV-shScr and CMV-miScr, not targeting
any sequence in the human genome, were used as negative
controls. Luciferase expression in the negative controls
was set at 100% and the relative inhibition of luciferase
reporters was calculated (Figure 3d,e,f ). CMV-shApoB1
and CMV-shApoB2 inhibited luciferase reporters by
22% and 8% respectively (Figure 3e,f ), which is similar
to the knockdown observed with CMV+6shLuc20-pA
(Figure 3d). By contrast, CMV-miApoB1 and CMV-
miApoB2 were found to inhibit luciferase reporters up
to 57% and 75% respectively (Figure 3e,f ). CMV-miLuc
was not more active than CMV+6shLuc20-pA even
though it was designed the same way as CMV-miApoB1
and CMV-miApoB2 (Figure 3d).
Quantification of siRNA molecules processed from the
different shRNA and miRNA scaffolds
Next, we wanted to determine if the inhibitory effect of
the shRNA and artificial miRNA constructs correlates
with the amount of processed siRNA molecules in the
cell. For siLuc, siApoB1 and siApoB2 sequences, small
RNA specific TaqMan assay was designed for detecting
the guide strand (Additional file 1: Table S1). Ten-fold
dilutions (100 pg – 1 fg) of the guide strand of each syn-
thetic siRNA oligo were used to create a standard line
(Figure 4a). All siRNA assays showed a clear exponential
correlation between the amplification pattern and the
amount of siRNA standard. The small RNA TaqMan
assay relies on the hybridization of stem-loop RT primers
to the mature guide strand and in some cases the method
could show insufficient specificity, amplifying the precur-
sor shRNA hairpin or nonspecifically binding to another
siRNA molecule. To exclude this possibility, we investi-
gated the ability of the siApoB1 and siApoB2 assays to
differentiate between the mature siRNA molecules, theirshApoB1 or shApob2 hairpin precursors and expression
plasmids by performing additional TaqMan experiments.
The primers and probes specifically amplified only the
corresponding synthetic siRNA standard and no aspecific
amplification was detected for the shRNA hairpin oligo
or expression plasmid suggesting that the small RNA
TaqMan assays were highly specific for the mature
siApoB1 or siApoB2 (Additional file 2: Table S2 and
Additional file 3: Table S3) Having confirmed that prop-
erly processed siRNA molecules can be specifically
detected, we proceeded with detection and quantification
of the amount of siRNA molecules per cell for H1-
shRNA, CMV-shRNA and CMV-miRNA constructs
(Figure 4b,c,d). For all constructs an amplification chart
was created and the amount of molecules was calculated.
The exponential amplification for H1-shLuc began at 25
cycles, while it began later for both CMV-shLuc and
CMV-miLuc (32 and 29 cycles respectively) (Figure 4b
left panel). The expression of siLuc molecules was 125-
fold lower when expressed as CMV-shLuc and 10-fold
lower when expressed as CMV-miLuc compared to H1-
shLuc, which resulted in 16686 siRNA molecules per cell
(Figure 4b right panel). The exponential amplification for
H1-shApoB1 began at 26 cycles, at cycles 32 for CMV-
shApoB1 and at 27 cycles for CMV-miApoB1 (Figure 4c
left panel). This represents 12-fold less molecules
expressed with CMV-shApoB1 and 2-fold less for CMV-
miApoB1 compared to H1-shApoB1, which resulted in
14838 siRNA molecules (Figure 4c right panel). siApoB2
molecules were not detected as efficiently as siLuc and
siApoB1 thus the exponential amplification started later:
for H1-shApoB2, it began at 29 cycles, at 36 cycles for
CMV-shApoB2 and at 34 cycles for CMV-miApoB2
(Figure 4d left panel). This represented 49-fold less mole-
cules expressed with CMV-shApoB2 and 32-fold less for
CMV-miApoB2 compared to H1-shApoB2, which
resulted in 1764 molecules per cell (Figure 4d right panel).
Endogenous ApoB mRNA knockdown
In order to assess the inhibitory effect of shApoB1, shA-
poB2, miApoB1 and miApoB2 constructs on endogen-
ous ApoB expression the mouse hepatoma Hepa1-6 cell
line was selected. Cells were transfected with H1-
shApoB1, CMV-shApoB1 and CMV-miApoB1 or with
their equivalent constructs having ApoB2 as a target.
Two days post transfection RNA was isolated and ApoB
mRNA expression was determined by RT-qPCR. Both
H1-shApoB1 and CMV-miApoB1 efficiently inhibited
ApoB mRNA up to 70% and 50% respectively
(Figure 5a). An even stronger effect was observed for
H1-shApoB2 and CMV-miApoB2 which inhibited ApoB
mRNA both up to 85% (Figure 5b). CMV-shApoB1 and
CMV-shApoB2 showed no inhibition of endogenous
ApoB expression, which confirms the results on
Figure 3 (See legend on next page.)
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Figure 3 Structure and knockdown efficacy of shRNA and miRNA hairpin constructs targeting luciferase and Apolipoprotein B100 (ApoB). (a,b,c)
Predicted stem-loop structures of shRNA and miRNA targeting luciferase: shLuc or miLuc and ApoB: shApoB or miApoB with guide strand highlighted in
grey. shRNA structure is described in Figure 1. miApoB consists of pri-mir-155 precursor sequence, where the mature mir-155 sequence was replaced with
the target sequence for luciferase or ApoB. ApoB1 and ApoB2 target different sequences in the ApoB gene. (d) Luciferase knockdown by CMV-shLuc and
CMV-miLuc. Renilla and Firefly luciferase were measured two days post-transfection with 100 ng shRNA or miRNA expressing plasmid and 2,5 ng Firefly
luciferase and 0,5 ng Renilla luciferase. H1-shLuc was used as a positive control. shScr and miScr served as negative controls and were set at 100%. Firefly
luciferase expression was normalized to Renilla luciferase expression. Data are represented as mean values±SD from three independent experiments
analyzed with the factor correction method [19] (e) Knockdown of Luc-ApoB1 reporter, containing in its 3’ UTR ApoB1 target sequence, by CMV-shApoB1
and CMV-miApoB1. Experimental setup was as described in (d) H1-shApoB1 was used as a positive control. (f) Knockdown of Luc-ApoB2 reporter,
containing in its 3’ UTR ApoB2 target sequence, by CMV-shApoB2 and CMV-miApoB2. Experimental setup was as described in (d) with the exception that
in this Renilla luciferase contained target sequence for ApoB2 and its expression was normalized to Firefly luciferase expression H1-shApoB2 was used as a
positive control. **p< 0.01 versus negative control (One-way ANOVA test with Bonferroni post test).
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the specificity of the designed constructs.
Discussion
There are few examples of successful shRNA expression
using pol II promoters. Although several requirements
for pol II shRNA expression have been established,
optimization and direct assessment of different hairpin
stem lengths, TSS and TTS have not been performed. In
the current study we evaluated the relevance of these
factors by positioning shRNAs targeting luciferase or
ApoB at +5 or +6 relative to the CMV TSS and added
the T5, pA or U1 TTS at the 3’ end of the hairpins. Add-
itionally, the same siRNA sequences were incorporated
in artificial miRNA scaffolds and direct evaluation be-
tween the silencing efficacy and processing of pol II-
expressed shRNA and miRNA was performed.
The nucleotide distance between the promoter, the
shRNA structure and the TTS determines the length
and sequence composition of the 5’ and 3’ overhangs of
the expressed hairpin. Both ends act as reference points
for recognition and proper processing by Dicer [17].
Initial rules published by Xia et al. include shRNA loca-
tion within 6 nt from the TSS and pA TTS [11]. Later
shRNA containing T5 and U1 TTS where also found to
be active when substituted for pA [13,18]. These set-
tings were used in our study to express shRNA from
the CMV promoter. The shLuc, shApoB1 and shApoB2
sequences have been previously validated as potent
inhibitors of their targets when expressed from the pol
III H1 promoter [15,21]. Surprisingly, all CMV-shLuc
constructs induced only a mild target inhibition when
the hairpin was placed at +6 TSS and T5 or pA TTS
were used. In contrast to previously published data, the
use of U1 TTS did not improve silencing efficacy. By
shifting the hairpin from +6 to +5 from TSS, thus min-
imizing the 5’ overhang, no significant improvement
was achieved and the effect was not dependent of TTS
used. Additionally, the CMV-shApoB1 and CMV-
shApoB2 hairpins were ineffective when the initial set-
tings of +6 TSS and pA TTS were used, indicating thatthose settings cannot be used as a general rule for pol
II shRNA expression.
The length of the shRNA hairpin stem has been
shown to play an important role in silencing efficacy as
it can lead to differential processing into multiple siR-
NAs [8,22,23]. In the current study we optimized the
pol II shRNA expression by testing stem lengths of 20,
21, 25, and 29 bp. Slight increase in silencing efficacy
was observed only when extending hairpin stem from
20 to 21 bp but not when the stem length was further
extended to 25 or 29 bp. Mcintyre et al. performed a
similar study by extending the shRNA stem length from
16 to 41 bp and looked at the core placement of the
shRNA [23]. While the processing of hairpins was
clearly dependent on the stem length, the activity was
primarily dependent on the sequence of processed pro-
ducts. Consistent with their data, our results suggest
that there is no strict correlation between the increase
in stem length and better silencing activity of the
shRNAs. Here, we focused only on pol II expression of
shRNA but an alternative approach would be to express
long hairpin RNA (lhRNA) where the stem length is
extended up to 300 bp [24-26]. Using lhRNA allows
generating multiple siRNA from a single transcript,
which can be used for viral infections or cancer, where
multiple sequences have to be targeted. To date, expres-
sion of active lhRNA from pol II promoter has not been
successful due to inefficient processing of the hairpins
by the RNAi machinery, and detailed studies on TSS,
TTS and hairpin location, similar to those for shRNA
are lacking.
An alternative to optimizing pol II expression of
shRNA is to use pre-miRNA scaffolds and replace the
mature miRNA sequence with siRNA targeting a gene of
interest. Cellular miRNAs are naturally expressed from
pol II promoters [1,27]. Therefore, when shLuc, shA-
poB1 and shApoB2 were expressed from the pri-mir-155
scaffold the knockdown efficacy was significantly
improved. Importantly, artificial miRNA have been
found to be less toxic in vitro and in vivo compared to




Figure 4 (See legend on next page.)
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Figure 4 Quantification of siRNA molecules expressed from H1-shRNA, CMV-shRNA and CMV-miRNA targeting luciferase and
Apolipoprotein B100. (a) Synthetic siRNA standard lines. siRNA- specific small RNA TaqMan was performed with dilution series of synthetic siLuc,
siApoB1 or siApoB2 molecules. Based on molecular weight of the synthetic siLuc, siApoB1 and siApoB2, the amount of molecules for each point
of standard line was calculated and plotted against CT value. (b) siLuc amplification plot (left panel) and expression in Hek293T cells (right panel).
RNA was isolated two days post-transfection with 1 μg H1-shLuc, CMV-shLuc or CMV-miLuc expressing constructs and siLuc-specific small RNA
TaqMan was performed. siRNA copy number was calculated using the synthetic RNA oligo standard line as described in (a) (c) siApoB1
amplification plot (left panel) and expression in Hek293T cells (right panel) after transfection with 1 μg H1-shApoB1, CMV-shApoB1 or CMV-
miApoB1 expressing constructs. Experimental set up as described in (b) (d) siApoB2 amplification plot (left panel) and expression in Hek293T cells
(right panel) after transfection with 1 μg H1-shApoB2, CMV-shApoB2 or CMV-miApoB2 expressing constructs. Experimental set up as described in
(b). Amplification data are presented from representative experiment from two independent experiments conducted with two technical
replicates. siRNA expression data are represented as mean values ± SD from 2 independent experiments conducted with two technical replicates.
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huntingtin mRNA and to avoid neurotoxicity caused by
overexpression of shRNA [14]. Similarly, incorporation
of a siRNA against spinocerebellar ataxia 1 protein into
an artificial miRNA abolished neuronal cell death
observed with a shRNA harboring the same siRNA se-
quence [6]. In a previous study we have provided evi-
dence for the efficacy of liver-specific expression of
artificial miRNA targeting ApoB in vivo and demon-
strated its advantages over the pol III-expressed shRNA
(Maczuga et al., manuscript submitted). In conclusion,
we and others have shown that pol II expression of arti-
ficial miRNA scaffolds is a more robust and promising
approach than pol II shRNA expression, probably due to
the specific structural characteristics of the miRNA.
An additional advantage of the use of artificial miR-
NAs is that several precursors can be expressed as clus-
ters from longer transcripts, allowing simultaneous
targeting of multiple genes [28]. This feature of the
miRNA is very important when mutation-prone viruses,
such as HIV-1 or HCV, are targeted or when several
disease-related genes need to be simultaneously silenced.
Moreover, miRNAs can be linked to the 3’ untranslated
region of a therapeutic gene, which is an additional ad-
vantage for therapeutic applications since it allows co-Figure 5 Comparison of endogenous ApoB mRNA knockdown by shA
Endogenous ApoB mRNA knockdown by H1-shApoB1, CMV-shApoB1 and
H1-shApoB2, CMV-shApoB2 and CMV-miApoB2 constructs qRT-PCR was pe
expressing constructs and ApoB mRNA levels were calculated relative to ac
and miScr served as negative controls and were set at 100%. Data are repr
analyzed with factor correction method [19]. **p< 0.01 versus negative codelivery of a codon-optimized gene together with a
miRNA targeting the disease-causing version of the
same gene. Such combinational therapy has been shown
for alpha1-antitrypsin (AAT) deficiency, in which a hair-
pin RNA targeting mutated AAT transcript was deliv-
ered together with codon-optimized AAT gene [29].
Quantification of the siRNA molecules expressed from
the H1-shRNA, CMV-shRNA or CMV-miRNA constructs
was highly specific and revealed differences in the amount
of processed siRNA molecules per cell. As expected, high-
est siRNA amounts were detected when the shRNAs were
expressed from the strong H1 promoter. However, when
the same shRNAs were expressed from the CMV pro-
moter, 12- to 125-fold less siRNA molecules were detected
indicating that either the shRNA was not efficiently tran-
scribed from the CMV promoter or that there was
impaired siRNA processing by the RNAi machinery. Sur-
prisingly, the amount of processed siRNA from the CMV-
miRNA constructs did not correlate with efficacy. For
example, CMV-miLuc yielded 1591 siLuc molecules per
cell and was completely ineffective in target knockdown
while CMV-miApoB2 yielded only 56 siApoB2 molecules
per cell and was highly efficient. A possible explanation
for this discrepancy is that the small RNA TaqMan assay
detects only one variant of the guide strand and althoughpoB1, shApoB2, miApoB1 and miApoB2in Hepa1-6 cells.
CMV-miApoB1 constructs (b) Endogenous ApoB mRNA knockdown by
rformed two days post-transfection with 1 μg of shRNA or miRNA
tin mRNA. H1-shApoB1 and H1-ApoB1 served as positive control. shScr
esented as mean values + SD from three independent experiments
ntrol (One-way ANOVA test with Bonferroni post test).
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in the CMV-shRNA and CMV-miRNA scaffolds, they can
still be processed differently. Indeed, our newest data
based on Next Generation Sequencing (NGS) of small
RNAs from cells transfected with H1-shApoB2 and CMV-
miApoB2 indicates differential processing and different
mature sequences from the two scaffolds (Maczuga et al.,
manuscript submitted). The siRNAs originating from the
H1-shRNA were more heterogeneous in cleavage sites and
length compared to the products originating from the
CMV-miRNA scaffold supporting the notion that Dicer
cleavage is less precise than the combination of Drosha
and Dicer. Unfortunately, NGS data from pol II-expressed
shRNA, which would allow verifying the processed siRNA
variants and their abundance, are still not available.
Conclusions
In summary, our results demonstrate that it is currently
difficult to draw rules for efficient pol II shRNA expres-
sion and processing. Optimization of the shRNA stem
length, TSS and TTS did not result in better silencing ef-
ficacy for any of the CMV-expressed shRNAs. On the
other hand, when identical predicted sequences were
incorporated in miRNA scaffolds, two out of three
sequences resulted in potent inhibition of luciferase
reporters and endogenous mRNA. Our data question
the application of the previously published rules for pol
II shRNA expression as general standards. The rules for
design of potent shRNA expressed from pol II promo-
ters are still far from clear and they can be used rather
as reference points. Still detailed empirical optimization
of hairpin location seems to be required for every target
and pol II promoter used. We consider that embedding
siRNA in artificial miRNA scaffold and expression from
pol II promoter is a better and approach than direct pol
II shRNA expression due to the intrinsic characteristics
of the miRNA structure rendering it a better substrate
for the RNAi machinery.Methods
DNA constructs
H1-shRNAs were made by annealing complementary oli-
gonucleotides and ligating them into the BglII and XhoI
sites of the pSuper vector (OligoEngine, Seattle, WA,
USA). The vector contains a stretch of five thymidines
(T5), which acts as the transcription termination signal.
Panel of shRNAs were designed to act as positive con-
trols: one shRNAs was designed that target Firefly luci-
ferase (H1-shLuc), two shRNAs were made that target
different regions of human ApoB gene (H1-shApoB1 and
H1-shApoB2). Additionally two negative controls shRNA
were deigned: one that do not target any gene in human
and mouse genome (H1-shScr) and one that target theGFP (H1-shGFP). All the sequences of oligonucleotides
used in this study are listed in Additional file 1: Table S1.
CMV-shRNA with different termination signals were
designed as followed. First different TTS (T5, pA or U1)
were annealed from complementary oligonucleotides and
ligated into the AccI and SphI sites of pVD23 which
includes the CMV promoter. Next, plasmids were digested
with SacI and NheI and complementary oligonucleotides
containing shRNA targeting GFP (shGFP) or Luciferase
(shLuc) were inserted. shLuc oligonucleotides were
designed to allow the hairpin transcription to start at +5
or +6 nucleotides after the TSS, which was considered as
+1. The final constructs were CMV+5shLuc-T5, CMV+6
shLuc-T5, CMV+5shLuc-pA and CMV+6shLuc-pA. For
U1 termination signal only CMV+6shLuc-U1 was cre-
ated. As negative controls CMV-shGFP-T5, CMV-shGFP-
pA and CMV-shGFP-U1 were made. GFP oligonucleotides
were designed that hairpin started at +6 from the TSS.
CMV-shRNAs with different stem length of the hair-
pin were designed as followed. CMV-shLuc20, CMV-
shLuc21, CMV-shLuc25 or CMV-shLuc29 were made by
annealing complementary oligonucleotides that create
the stem-loop structure of 20, 21, 25 and 29 bp respect-
ively and ligating them into the BamHI and XhoI sites of
the pSilencer 4.1 CMV vector (Life Technologies, Grand
Island, NY). Constructs contained either the pA or the
U1 termination signal. To create the CMV-shApoB1 and
CMV-siApoB2, siRNA sequences from shApoB1 and
shApoB2 were cloned by annealing complementary oli-
gonucleotides and ligating them into the BamHI and
XhoI sites of the pSilencer 4.1 CMV vector with pA ter-
mination signal. As the negative control, pSilencer 4.1
CMV control (Life Technologies, Grand Island, NY)
plasmid was used, named CMV-shScr.
To create the artificial miRNA expressing vectors,
siRNA sequences from shLuc, shApoB1 and shApoB2
were cloned into the pri-mir-155 backbone of pcDNA6.2-
GW/EmGFP-miR (Life Technologies, Grand Island, NY)
by annealing complementary oligonucleotides and ligation
into BamHI- and XhoI-digested pcDNA6.2 plasmid and
named respectively CMV-miLuc, CMV-miApoB1and
CMV-miApoB2. As the negative control pcDNA6.2-GW/
EmGFP-miR-neg control (Life Technologies, Grand
Island, NY) was used, named CMV-miScr. The Mfold pro-
gram was used to determine the secondary structure of all
RNA transcripts [30].
Reporter constructs that were used for luciferase knock-
down are Firefly luciferase pGL4 (Promega, Madison, WI)
and pRL Renilla (Promega, Madison, WI) under control of
the CMV promoter. Luc-ApoB1 reporter, containing in
its 3’ UTR a fragment of 239 nucleotides of human ApoB
(NM_000384, 9362–9600) sequence was made, by clon-
ing of the ApoB sequence, that was PCR amplified with
primers pr565f and pr566r in the XhoI and NheI sites of
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http://www.biomedcentral.com/1472-6750/12/42pGL4 plasmid. For The Luc-ApoB2 containing in the
3’UTR of siCheck2 vector (Promega, Madison, WI) 1851
nucleotides of the last exon from the human ApoB has
been described previously.
Cell culture and transfections
The human embryonic kidney (HEK)293 T and mouse
hepatoma Hepa1-6 cell lines were maintained in Dulbec-
co’s modified Eagle’s medium (DMEM; Life Technologies,
Grand Island, NY) containing 10% fetal calf serum, 100 U/
ml penicillin and 100 U/ml streptomycin, at 37°C and 5%
CO2. For luciferase assays, endogenous ApoB knockdown
assays, and siRNA expression analysis, cells were seeded
in 96- or 24-well plates at a density of 3*104 or 1.2*105
cells per well, respectively, in DMEM one day prior trans-
fection. Transfections were performed with Lipofectamine
2000 reagent (Life Technologies, Grand Island, NY)
according to the manufacturer’s instructions.
Luciferase assays
Cells were co-transfected with 100 ng shRNA or miRNA
expressing plasmid and respectively 2,5 ng Firefly lucifer-
ase or Luc-ApoB1 and 0,5 ng Renilla or 50 ng Luc-
ApoB2 reporter. Transfected cells were assayed at 48 hr
post-transfection in 20 μl 1x passive lysis buffer (Pro-
mega, Madison, WI) Firefly and Renilla were measured
luciferase activities with the Dual-Luciferase Reporter
Assay System (Promega, Madison, WI). For luciferase
knockdown calculations, H1-shLuc was used as a positive
control. CMV-shScr, CMV-shGFP or CMV-miScr served
as negative controls and were set at 100%. For luciferase-
and ApoB1- and ApoB1 targeting constructs Firefly luci-
ferase expression was normalized to Renilla luciferase ex-
pression. For ApoB2-targeting constructs Renilla
luciferase expression was normalized to Firefly luciferase
expression since the siCheck2 plasmid was used.
RNA isolation and quantitative real-time RT-PCR
To determine endogenous ApoB mRNA knockdown by
shApoB and miApoB constructs in vitro, Hepa1-6 cells
were transfected with 1 μg shApoB1, shApoB2, miA-
poB1 or miApoB2 and total RNA was isolated from cells
48 hr post-transfection using the Nucleospin kit (Clon-
tech, Mountain View, CA). Genomic DNA (gDNA) was
removed by DNase treatment using TURBO DNase
(Ambion, Austin, TX). First strand cDNA was reverse
transcribed using random hexamer primers with the
Dynamo kit (Finnzymes, Espoo, Finland). Real time PCR
amplification was performed with ApoB- and beta actin-
specific primers (Additional file 1: Table S1). PCR reac-
tion conditions were: 95°C for 10 min, followed by 40
cycles of 15 sec at 95°C and 1 min at 60°C. The assays
were performed on ABI 7000 or ABI 7500 (Applied Bio-
systems, Foster City, CA). ApoB expression levels werenormalized to beta actin as an internal control, and the
relative gene expression 2-ΔΔCt method of Livak and
Schmittgen was used for analysis of PCR data [31].
siRNA detection by small RNA TaqMan assay
RT reactions for siLuc, siApoB1 and siApoB2 expression
were performed with the TaqMan MicroRNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA)
using 10 ng RNA isolated from cells transfected with
shRNA or miRNA expression plasmids and 3 μl custom-
made specific RT-stem-loop primers (Applied Biosystems,
Foster City, CA) according to the manufacturer’s instruc-
tions. The TaqMan assay was done in 20 μl using 1,33 μl
cDNA, 1-μl custom-made siRNA-specific primer with
FAM-labeled fluorogenic probe (Applied Biosystems) and
10 μl TaqMan 2× Universal PCR Master Mix (Applied
Biosystems). For determining the assay specificity, 10 ng
of the indicated oligo or expression plasmid was added to
the TaqMan reaction. Amplification of the beta actin gene
was used as a RNA quality and loading control. siRNA
copy number per cell was calculated based on the amplifi-
cation plot of a dilution series of synthetic siRNA standards
(IDT, Coralville, IA). Tenfold dilutions (100 pg – 1 fg) of
the guide strand of the synthetic siRNA oligo were used to
create a standard line. The copy number of each dilution
was calculated according to the formula 1 mol = 6.02 × 1023
molecules. The trend line value of the standard line
was used to calculate the siRNA copy number per cell,
assuming 15 pg RNA per cell [32].
Additional files
Additional file 1: Table S1. Oligonucleotides used in this study.
Additional file 2: Table S2. Determination of siApoB1 RT primers and
TaqMan probe specificity on siApoB1, shApoB1 hairpin precursor,
shApoB1- and miApoB1-expression plasmid and siApoB2.
Additional file 3: Table S3. Determination of siApoB2 RT primers and
TaqMan probe specificity on siApoB2, shApoB2 hairpin precursor,
shApoB2- and miApoB2-expression plasmid and siApoB1.
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